Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Milestone Pharmaceuticals (Nasdaq: MIST) granted 65,000 stock options as a material inducement under its 2021 Inducement Plan on a Nov 3, 2025 grant date.

The options have an exercise price of $1.85 per share (equal to the closing price on the grant date) and vest over four years: 25% on the one‑year anniversary of the vesting commencement date, then the remainder in 36 equal monthly installments. Awards are subject to continuous service and the Plan's grant agreements. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) and the Plan is designated for inducement awards to new hires or those returning after bona fide non‑employment.

MONTREAL and CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 65,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of a new employee. 

The Options have a grant date of November 3, 2025, and an exercise price of $1.85 per share, which is equal to the closing price of Milestone’s common shares on the grant date. The shares subject to the Options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter.

The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.

The foregoing equity award was granted as an inducement material to the employee entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individual’s entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4).

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for the treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.

Contact:
Kevin Gardner kgardner@lifesciadvisors.com

FAQ

How many options did Milestone Pharmaceuticals (MIST) grant on Nov 3, 2025?

Milestone granted 65,000 options with a grant date of Nov 3, 2025.

What is the exercise price of the MIST inducement options granted Nov 3, 2025?

The exercise price is $1.85 per share, equal to the closing price on the grant date.

What is the vesting schedule for the 65,000 MIST options granted as an inducement?

The options vest over four years: 25% at the one‑year anniversary, then the balance in 36 equal monthly installments.

Are the Nov 3, 2025 MIST option awards conditioned on continued employment?

Yes, the awards are subject to the holder’s continuous service through each vesting date and to the Plan terms.

Under which Nasdaq rule were the Milestone (MIST) inducement grants made?

The grants were made under Nasdaq Listing Rule 5635(c)(4) for material inducements to new employees.

What is the purpose of Milestone’s 2021 Inducement Plan used for the MIST awards?

The Plan is used exclusively to grant equity awards as material inducements to individuals not previously employed or returning after bona fide non‑employment.